microRNAs participate in a wide variety of physiological and pathological cellular processes. Recent studies have established a link between a specific group of microRNAs and hypoxia, a key feature of the neoplastic microenvironment. A significant proportion of the hypoxia-regulated microRNAs (HRMs) are also overexpressed in human cancers, suggesting a role in tumorigenesis. Preliminary evidence suggests that they could affect important processes such as apoptosis, proliferation and angiogenesis. Several HRMs exhibit induction in response to HIF activation, thus extending its repertoire of targets beyond translated genes. In the present review, we discuss the emerging roles of HRMs in oxygen deprivation in cancer context.
Small Size Regulators with Far-Reaching Impact
MicroRNAs are currently thought to regulate the expression of most genes and consequently play critical roles in the coordination of a wide variety of processes, including differentiation, proliferation, death and metabolism. [1] [2] [3] They exert their actions at post-transcriptional level, either via translational repression and/or mRNA degradation. 4, 5 As the 'noncoding RNA revolution' continues to unfold, a large number of microRNAs have been associated with tumorigenesis and suspected to mechanistically participate in this complex process. Thus, specific microRNA patterns have been described in tumors, and in some cases shown to correlate with their clinico-pathological features. Additionally, a significant number of microRNAs are encoded within fragile sites, regions of amplification, or common breakpoint regions associated with human cancers. [6] [7] [8] [9] [10] [11] [12] Regulatory Mechanisms of microRNA Expression: the Role of Hypoxia
The information about specific regulation of microRNAs has comparatively lagged behind, in contrast to the wealth of publications about their biological effects. Recent studies showed that select microRNAs can be controlled by transcription factors involved in the regulation of 'classic genes' in response to various endogenous and exogenous stimuli. For example, the oncogene product and transcription factor c-MYC activates the miR-17-92 cluster, and this mechanism plays an important role in tumor formation. 13 Similarly, E2F transcription factor family was also found to regulate this oncogenic cluster.
14 Thus, it is conceivable that engaging a microRNA component is a more general feature of transcription factors action, and recent work addressed such a mechanism in the context of the hypoxia response.
Hypoxia is an essential feature of the neoplastic microenvironment. Tumors with extensive low oxygen tension tend to exhibit poor prognosis and resistance to conventional therapy. The molecular mechanisms of response to hypoxia are extremely complex, a key role being played by a transcriptional regulator, hypoxia-inducible factor (HIF), which orchestrates the expression of a wide variety of genes thought to be critical for adaptation to low oxygen. [15] [16] [17] [18] [19] [20] While specific gene induction by low oxygen has arguably dominated hypoxia research, more recently the study of gene repression by hypoxia has received increasing attention. One of the interesting features of the latter process is its relative selectivity. Thus, a large percentage of genes continue to be expressed at quasi-normoxic levels, while the translation/ transcription of others is significantly suppressed. Our working hypothesis has been that microRNAs could be a part of this process (Figure 1) .
Studies from our group identified a set of hypoxia-regulated microRNAs (HRMs), providing an additional link between a tumor-specific stress factor and gene expression control. The HRM group includes: miR-21, 23a, 23b, 24, 26a, 26b, 27a, 30b, 93, 103, 103, 106a, 107, 125b, 181a, 181b, 181c, 192, 195, 210 and 213, which were consistently induced in response to hypoxia in the breast and colon cancer cells tested. 21 Our study selected only microRNAs exhibiting consistent upregulation in at least two cell lines and at several time points in hypoxia, potentially increasing the stringency of the screen. Three additional articles reported microRNAs that respond to low oxygen with some notable similarities, including miR-210, miR-30b, 93 and 181b. [22] [23] [24] It is also true, however, that a significant number of microRNAs differed between the studies, which is not necessarily surprising, given the differences in the cellular backgrounds and technology employed, both being a recognized source of variability. An additional difference was in the experimental conditions employed by the different groups: hypoxia mimetics, 22 versus 1% oxygen for 1 h, 23 versus 5% oxygen for 8 h, 23 versus 0.2% for various periods of time from 8-48 h. 21 In addition to the microRNAs that respond to hypoxia by upregulation, a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. [22] [23] [24] In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpublished).
An interesting case is represented by the members of let-7 family, which seem to exhibit contrasting patterns of response during hypoxia, with the caveat that the findings were reported in different cell types and by different groups. Thus, let-7g, let-7e and let-7i were identified as hypoxia-inducible whereas let-7a, c, d, e, f and g levels decreased during hypoxia exposure. 22, 23 In our hands, several let-7 forms (f, g, i) exhibited contrasting changes in different colon and breast cancer cell lines (R Kulshreshtha et al., unpublished), suggesting that the let-7 family could contain microRNAs that respond to hypoxia in a more cell-specific manner. A summary of all the microRNAs reported as hypoxia-responsive (either by induction or repression) is provided in Table 1 (for more  detailed information, see Supplementary Tables 1 and 2 ).
Our study experimentally confirmed an important regulatory role for HIF, at least for some hypoxia-induced microRNAs, such as miR-210, 26 and 181. The strategy employed a combination of HIF transduction, chromatin immunoprecipitation and luciferase-based reporters driven by fragments of select HRM promoters. 21 Delineating the promoter regions of microRNAs, where relevant transcription factors such as HIF bind, is a necessary step for an expanded understanding of microRNA expression control. The main challenge comes from the fact that only few microRNA promoters have been identified experimentally. [25] [26] [27] In a preliminary analysis of the promoters of all known and predicted microRNAs, we predicted HIF-binding sites by position weight matrix approach. 21 While our methodology analyzed the 5 kb promoter region of all the microRNAs, the promoter regions can span much longer regions. The analysis, performed separately for individual types of HIFbinding consensuses (V$HIF_Q3 and V$HIF_Q5) revealed that the HRMs (as a group) contains significantly more microRNAs with at least one HIF site than the average random 23 microRNAs.
Additionally, approximately 6% of the human microRNAs exhibit HIF sites significantly conserved across 17 species, which could reflect functional importance. 28 Such searches could help us identify additional HRMs, which were likely missed by the original array-based screen.
Recently, additional transcription factors that under certain conditions respond to hypoxia/anoxia, such as p53 and NF-kB, have been shown to affect the expression of select microRNAs. 29, 30 It is however premature to state whether or not such pathways could play significant role in the hypoxic response.
We also identified additional candidate transcription factor sites in the proximity of select HRM, some of them exhibiting a high degree of evolutionary conservation, suggesting a biologically important role. An example for miR-210 is given in Figure 2 , showing candidate sites for several transcription sites (Oct-C, AP2, PPAR g and E2F) which could potentially regulate its expression as part of the hypoxia response or in response to unrelated stimuli.
Towards Identification of Cellular HRM Targets
Identification of targets with biological impact remains without doubt a highly complex endeavor in the study of microRNAs. Several programs for target gene prediction are currently available, such as PicTar (pictar.bio.nyu.edu), TargetScan (www.targetscan.com) and miRBase (http://microrna.sanger. ac.uk/cgi-bin/targets/v1/search.pl). [31] [32] [33] They employ different algorithms and ranking criteria and are known to produce only a partially overlapping set of candidates.
Figure 1 Proposed model implicating select microRNAs in the hypoxia response
In the case of hypoxia-regulated microRNAs, in silico searches reveal a highly complex spectrum of candidate targets, including genes involved in proliferation, apoptosis, DNA repair, chromatin remodeling, metabolism and migration. Each HRM is predicted to downregulate in excess of 10 genes, sometimes as many as 200, which could confound the effort to identify biologically relevant targets.
One set of targets worth pursuing is cell death regulators, given the importance of this process in a stressful environment, such as hypoxia. Using the available prediction programs, several key genes of the apoptotic response were found to be potentially targeted by HRMs: PAR-4 (miR-26, 30, 181), PCDC10 (miR-103/107, miR-181), BID (miR-23), BIM (miR-24); CASP3 (miR-30), CASP 7 (miR-23), APAF1 (miR-27), BAK1 (miR-26), Bnip3L (miR-23) (Figure 3) . Conversely, one of the best-documented antiapoptotic genes (Bcl2) is an experimentally-confirmed target of miR15 and 16. These microRNAs were found to respond to hypoxia by downregulation, at least in one cell type. 22, 34 One could therefore predict a mechanism whereby an increase in Bcl2 in hypoxia occurs, in part, by microRNA downregulation.
We do not imply, however, that HRMs exhibit a general antiapoptotic effect in hypoxia. Indeed, it is entirely conceivable that any given HRM could feed into downstream pathways containing both pro-and antiapoptotic genes. Which side the balance will shift could depend on a variety of factors, including cellular context and additional stimuli.
Another process known to be affected by hypoxia is proliferation, since many cell types undergo cell cycle slowdown or arrest during oxygen deprivation. A multitude of cell cycle genes are in silico HRMs targets, a few examples being: cdc25A (miR-21, miR-103/107), cyclin D2 (miR-26, miR-103/ 107), cyclin E1 (miR-26), cyclin H (miR-23), cdk6 (miR-26, miR-103/107). One possibility that remains to be tested is that coordinated induction of HRMs in hypoxia exhibits an independent regulatory impact on cell cycle.
A potential microRNA target of particular importance is VEGF, arguably the most studied angiogenic factor and wellestablished therapy target. For this gene, a group of candidate regulatory microRNAs have been identified recently: miR-16, miR-20, let-7b, miR-17-5p, miR-27, miR-106, miR-107, miR-193, miR-210, miR-320 and miR-361. 22 Interestingly, most of these microRNAs were found to respond to hypoxia, which could lead to an extra layer of complexity in the angiogenic response.
The number and variety of targets for each miR raises an experimental challenge, one prediction being that manipulation of any individual target will fail to fully capture the phenotypic impact of the corresponding miR in low oxygen. Moreover, it is entirely logical that experimental manipulation of any given microRNA in hypoxia will fail to reproduce the effect of coordinated changes of all the HRMs.
Towards Future Applications in Clinical Oncology
Recent investigations have dissected a large number of cancers (breast, lung, colon, stomach, prostate carcinomas and pancreatic endocrine tumors) for microRNA expression and identified specific alterations compared to normal cells. 35 Interestingly, the majority of HRMs are also overexpressed in at least some types of tumor types, suggesting that hypoxia represents a contributing element for microRNA alterations in cancer.
The patterns of microRNA alterations reported in cancer versus normal tissues is very likely the sum of a large variety of highly complex molecular signals, including activation of oncogenic pathways and microenvironmental factors (hypoxia, pH alterations). Given the relatively low number of microRNAs compared to the 'conventional genes', one could anticipate that microRNA profiles could help provide a readout of the activated signaling pathways in individual tumors. However, for such an effort to become feasible, a detailed understanding of the tumor-relevant regulators is of utmost importance. Another direction of microRNA research in a tumor context is towards novel pharmacologic approaches. Although the traditional drug targets have been protein products, the recent development of microRNA derivatives with increased stability and binding efficiency, such as AMOs (antimicroRNA oligonucleotides) and LNAs (locked nucleic acids) represent potentially important developments for such purpose. [36] [37] [38] For example, targeting an HRM that plays a survival role in hypoxia could provide a new angle in targeting a notoriously refractory fraction of tumor cells. Moreover, manipulation of select microRNAs could synergize with conventional therapies. For example, overexpression of miR-21 (identified as HRM), enhances the effect of gemcitabine on cholangiocarcinoma cells. 
